Trial Profile

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Glofitamab (Primary) ; Mosunetuzumab (Primary) ; Obinutuzumab (Primary) ; Oxaliplatin (Primary) ; Tocilizumab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions
Sponsors Roche

23 Nov 2021 Status changed from active, no longer recruiting to completed.
20 Oct 2021 Planned End Date changed from 4 Sep 2021 to 26 Oct 2021.
20 Oct 2021 Planned primary completion date changed from 4 Sep 2021 to 26 Oct 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com